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Next-generation sequencing is transforming our understanding of
human genetic variation but assessing the functional impact of
novel variants presents challenges. We analyzed missense variants
in the integrin αIIbβ3 receptor subunit genes ITGA2B and ITGB3
identified by whole-exome or -genome sequencing in the Thrombo-
Genomics project, comprising ∼32,000 alleles from 16,108 individuals.
We analyzed the results in comparison with 111 missense variants in
these genes previously reported as being associated with Glanzmann
thrombasthenia (GT), 20 associated with alloimmune thrombocytope-
nia, and 5 associated with aniso/macrothrombocytopenia. We identi-
fied 114 novel missense variants in ITGA2B (affecting ∼11% of the
amino acids) and 68 novel missense variants in ITGB3 (affecting ∼9%
of the amino acids). Of the variants, 96% hadminor allele frequencies
(MAF) < 0.1%, indicating their rarity. Based on sequence conserva-
tion, MAF, and location on a complete model of αIIbβ3, we selected
three novel variants that affect amino acids previously associated
with GT for expression in HEK293 cells. αIIb P176H and β3 C547G
severely reduced αIIbβ3 expression, whereas αIIb P943A partially re-
duced αIIbβ3 expression and had no effect on fibrinogen binding. We
used receiver operating characteristic curves of combined annotation-
dependent depletion, Polyphen 2-HDIV, and sorting intolerant from
tolerant to estimate the percentage of novel variants likely to be
deleterious. At optimal cut-off values, which had 69–98% sensitivity
in detecting GT mutations, between 27% and 71% of the novel αIIb
or β3 missense variants were predicted to be deleterious. Our data
have implications for understanding the evolutionary pressure on
αIIbβ3 and highlight the challenges in predicting the clinical signifi-
cance of novel missense variants.
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Next-generation sequencing is transforming our understandingof human genetic variation (1) and providing profound insights
into the impact of both inherited and de novo variants on human
health (2, 3). At the same time, the data from these studies present
serious challenges in providing information to individuals who are
found to have variant forms of different proteins. To highlight these
challenges, in this report we describe our experience in analyzing
missense variants of the platelet αIIbβ3 integrin receptor from The
Human Genome Mutation Database (HGMD), the 1000 Genomes
project (1000G), the United Kingdom 10K Whole Exome Se-
quencing project (U.K.10KWES), the United Kingdom 10KWhole
Genome Sequencing project (U.K.10KWGS), and The National
Heart, Lung and Blood Institute Exome Sequencing Project (ESP);
the latter four sources encompass ∼32,000 alleles derived from
16,108 individuals.
The αIIbβ3 receptor has a number of virtues as a model system.
First, it is required for hemostasis because platelet aggregation
requires cross-linking of the activated form of αIIbβ3 by macro-
molecular ligands (4). Thus, defects in its biogenesis, activation,
or ligand binding lead to the rare bleeding diathesis Glanzmann
thrombasthenia (GT), an autosomal recessive disorder (5, 6).
Patients with GT come to medical attention because of their
hemorrhagic symptoms, and thus have been carefully analyzed
clinically and with tests of platelet function for nearly 50 y (5, 7).
The biochemical and molecular abnormalities in GT have been
studied for nearly 40 y (4, 6, 8–10). In the past 10 y, high-res-
olution crystallography, electron microscopy, and computa-
tional studies of the αIIbβ3 receptor have provided atomic-level
information on the correlation between receptor structure and
function (11–21). In addition, ethnic groups with relatively high
prevalence of GT have been defined that share the same ge-
netic abnormality based on founder mutations, and the dates
that some of the mutations entered the population have been
estimated (22–28). An on-line registry of GT abnormalities,
including patient phenotypes was developed in 1997 (29) and
currently contains 51 αIIb and 43 β3 missense variants linked to
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the disorder (sinaicentral.mssm.edu/intranet/research/glanzmann).
The frequency of GT in the general population has not been
established but it has a world-wide distribution, and based on data
from hematologic practices, it is rare except in areas with a high rate
of consanguineous mating (30).
Second, alloimmune disorders, including neonatal thrombocyto-
penia and posttransfusion purpura, due to amino acid substitutions
in either αIIb or β3, have been characterized at the molecular
biological level and correlated with mechanisms of immunologic
recognition (31).
Third, inherited macrothrombocytopenia and anisothrombocy-
topenia have been associated with heterozygous missense variants
or deletions in αIIb or β3. All of these appear to induce con-
stitutive activation of the receptor and impair proplatelet for-
mation (32–38).
Fourth, αIIbβ3 contributes to pathological platelet thrombus
formation in human ischemic cardiovascular disease and αIIbβ3
is a validated target for antithrombotic therapy (39–41).
Fifth, αIIbβ3 is a member of the large integrin family of recep-
tors, which includes 24 receptors derived from 18 α- and 8 β-sub-
units (41, 42). These receptors are involved in important biologic
processes, including development, cell migration, homing, cell
survival, and adaptive immunity (41–43). More is known about the
structure–function relationships of αIIbβ3 than the other members
of the group, and so it serves as the paradigmatic integrin receptor
(44, 45).
Sixth, 3D molecular models have been built based on crys-
tallographic and NMR data to analyze the effects of novel amino
acid substitutions on receptor structure and function and the gen-
eration of alloantigens (15, 46–53). The data from these models and
assessments of the severity of the amino acid change in the variants
have the potential to aid in predicting whether a novel variant is
likely to affect receptor function and immunogenicity (54–59).
Results
Glanzmann Thrombasthenia. The ThromboGenomics αIIbβ3 com-
pendium developed from the five databases (HGMD, 1000G,
U.K.10KWES, U.K.10KWGS, and ESP) contains 319 missense
variants in either αIIb or β3, and these are reported in Table S1 A
and B. Putative mutations producing GT were considered to be
confirmed as disease-causing if they were associated with a GT
phenotype and the negative impact of the mutation on αIIbβ3
expression, activation, and/or ligand binding was established
in a recombinant system based on a review of the publications
describing each of the mutations. Mutations reported in association
with a GT phenotype that were not studied in a recombinant system
were considered presumptive GT mutations. Because some patients
with GT have at least one allele with no exonic variant, it is possible
that a nondeleterious (silent) variant that just happened to be on
such an allele will be mistaken for a GT-causing variant. This
possibility is highlighted by the identification of a silent variant with
a relatively high frequency (1%) on an allele in a patient with
GT that had no other exonic variants (60). This variant might
have been misidentified as disease-causing if its functional con-
sequences were not analyzed in a recombinant expression system.
A total of 111 GT missense mutations were identified (56 in
αIIb and 55 in β3), of which 52 were considered confirmed and
59 presumptive. The locations of these mutants on the complete
αIIbβ3 molecular model are indicated by green spheres in Fig. 1
and Movie S1. For each of these mutations, we analyzed the de-
gree of conservation of the substituted amino acid across species
(based on a scale of 0–1, with 1 being the most conserved). A
mutation score was then assigned to each missense mutation as an
indication of the severity of the amino acid change (based on a
scale from 0 to 1, with 0 being the most severe), that is, taking into
account the likely amino acid substitutions during evolution. The
results are shown in Fig. 2, with green dots indicating the GT
mutants, and the different dot sizes indicating the severity of the
variant. The majority of disease-causing GT missense mutations
involve highly conserved amino acids (scores at or near 1.0) and
severe amino acid changes that are less tolerated evolutionarily
(55% of variants responsible for GT have mutation scores <0.4).
It is notable that not one of the established GT mutations was
identified on any of the up to ∼32,000 alleles analyzed in the four
WES and WGS studies represented in the databases, suggesting
that all of these GT mutations have allele frequencies less than
0.01% in the studied populations.
Alloantigens. The recognized alloantigens on αIIb and β3 are
listed in Table S2 and shown as orange spheres in Fig. 1 and on
the complete αIIbβ3 molecular model in Movie S1. The αIIb
HPA-3b/Baka/b (I874S) alloantigen is by far the most common
polymorphism, being found in 37% of the alleles and identified
in individuals in all five databases. Three of the other reported
Fig. 1. Model of αIIbβ3 with Glanzmann thrombasthenia mutations (green spheres), macro/anisothrombocytopenia mutations (magenta spheres), alloan-
tigens (orange spheres), and novel missense variants (gray spheres).
2 of 10 | www.pnas.org/cgi/doi/10.1073/pnas.1422238112 Buitrago et al.
αIIb alloantigens were identified in at least one of the four WES
and WGS studies in addition to HGMD, and they had minor
allele frequencies (MAFs) of 0.4% (HPA-27b/Cab3,Ak-L872M),
0.2% (HPA-9b/Max-V868M), and 0.03% (HPA-20b/Kno-T650M).
Two of the reported αIIb alloantigens (HPA-24b/Cab2,In-S503N
and HPA-22b/She,Sey-K195T) were not identified in any of the
four studies and thus presumably have MAFs < 0.01% in the
studied populations. HPA-1b/PlA2-L59P was the most common
β3 alloantigen with an MAF of 14%. The other β3 alloantigens
had MAFs of 0.9% or less and only HPA-6b/Ca/Tua-R515Q was
identified in all four WES and WGS studies. When analyzed on
the basis of amino acid conservation, compared with GT missense
mutations, the variants responsible for the alloantigens (orange
dots in Fig. 2) were less likely to affect highly conserved amino
acids or to exhibit severe amino acid changes (40% of variants
responsible for alloantigens have a mutation scores <0.4; differ-
ences in conservation score values between GT and alloantigens:
P = 9 × 10−5; difference in location = 0.25; Wilcoxon rank sum test).
Macro/Anisothrombocytopenia. Five heterozygous αIIbβ3 missense
mutations affecting four different amino acids (αIIb G1022C,
R1026Q, and R1026W; β3 L744P and D749H), along with three
different deletions, have been associated with macrothrom-
bocytopenia or platelet anisocytosis and variable abnormalities in
platelet function and clinical hemorrhage (32–38). The corre-
sponding positions on the complete αIIbβ3 molecular model are
shown as magenta spheres in Fig. 1 and Movie S1. All of the
mutations appear to result in constitutive activation of the receptor,
which in turn impairs proplatelet formation. None of these muta-
tions was identified in the four WES and WGS databases, sug-
gesting that they, like the mutations causing GT, are likely rare
(MAF < 0.01%). The conservation and mutation scores for these
amino acids are shown in Fig. 2.
Novel Variants.A total of 114 novel missense variants in αIIb and 68
novel missense variants in β3 were identified. These are shown as
gray spheres in Fig. 1 and on the complete αIIbβ3 molecular model
in Movie S1. In total, 11.2% of the 1,025 amino acids in mature αIIb
and 8.7% of the 784 amino acids in mature β3 were mutated. Only
3.8% of the variants had MAFs > 0.1%, indicating their relative
rarity, consistent with the expectation under the Fisher-Wright
model (61) that most variants are rare. Six αIIb amino acids were
mutated twice (40 T/I and T/A, 369 H/Q and H/D, 433 R/C and
R/H, 543 R/W and R/Q, 728 A/T and A/V, and 988 R/W and R/Q)
as were two β3 amino acids (14 V/L and V/M and 186 P/S and P/L)
among the novel variants and the previously described incidental
nondisease-causing variants. The severity of the amino acid change
and the conservation across species of the reference amino acid of
each variant are shown in Fig. 2 (gray dots). Compared with the GT
missense mutations, there was greater representation of variants at
less conserved amino acids and, in general, the variants produced
less severe amino acid changes (30% of the novel variants have
mutation scores ≤ 0.4).
Assessment of the Effect of Three Novel Variants on αIIbβ3 Expression
and Function. Five of the novel variants in our study affected an
amino acid in αIIb previously reported to be associated with GT
(P176H, L214F, H813L, L830F, and P943A) and two affected an
amino acid in β3 previously reported to be associated with GT
(R131W and C547G). The allele frequency for P943A was 0.46%,
whereas it was 0.01% or less for the other variants. It is notable
that αIIb P176 appears to be a mutational hotspot because four
patients from three ethnically distinct kindreds (Mennonite,
Dutch, and Italian) have been reported to have P176A mutations
and a Chinese GT patient has been reported with a P176L mu-
tation (62, 63).
We assessed the effect of the three variants with the most
severe variant scores, αIIb P176H and P943A, and β3 C547G, by
expressing them in HEK293 cells and analyzing both receptor
expression and the ability of the receptor to bind fibrinogen when
activated with the reducing agent DTT (53). Fig. 3A shows the
immunoblot data from the cell lysates. The WT αIIbβ3 bands
correspond to proαIIb, mature αIIb (which aligns with platelet
αIIb), and β3 (which migrates slightly slower than platelet β3
because it contains a V5 tag). The αIIb P943A variant expressed
similar amounts of proαIIb, but reduced amounts of mature αIIb,
suggesting a partial defect in αIIbβ3 maturation. In contrast, the
αIIb P176H variant showed a dramatic reduction in proαIIb ex-
pression and virtually no mature αIIb, and the β3 C547G variant
resulted in a profound decrease in β3 expression. Flow cytom-
etry using an antibody specific for the αIIbβ3 complex (mAb 10E5)
confirmed that the P943A variant produced a partial reduction in
αIIbβ3 expression and that the other two variants produced pro-
found reductions in surface expression of the αIIbβ3 complex
Fig. 2. Analysis of the degree of conservation of the substituted amino acids across species (based on a scale of 0–1, with 1 being the most conserved). A
mutation score is also assigned to each missense variant as an indication of the severity of the amino acid change (based on a scale from 0 to 1, with 0 and the
larger dot size indicating the most severe variant), that is, taking into account likely amino acid substitutions during evolution. Circles identified as 0.2
represent mutations scores between 0–0.2, those identified as 0.3 represent mutation scores between 0.2–0.3, and so forth.
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(Fig. 3B). The cells expressing the αIIb P943A variant were then
further tested for their ability to bind fibrinogen in the presence
of DTT. When the amount of fibrinogen bound was normalized
for αIIbβ3 expression, the αIIb P943A variant was found to bind as
much fibrinogen as normal αIIbβ3 (Fig. 3C), suggesting that this
variant partially affects expression, but does not alter receptor
function.
Novel Variants Affecting Amino Acids Mutated in Reported Alloantigens.
We identified two novel variants affecting the same amino acid
responsible for an alloantigen, β3 R515W affecting the same amino
acid as HPA-6b (R515Q) and β3 R662H affecting the same amino
acid as HPA-11b (R662C). Both novel variants were identified in
only one of the studies. R515W has an allele frequency of 0.1%
among the 32,216 alleles analyzed, whereas the alloantigen R515Q
has an allele frequency of 0.01% based on analysis of 13,306 alleles.
R662H has the same allele frequency as the alloantigen variant
R662C (0.02%).
Predicting the Consequences of Individual Variants. A number of
algorithms have been developed to predict whether a given amino
acid substitution is likely to be deleterious—that is, whether it will
alter expression or function. We used three different commonly
used algorithms: combined annotation-dependent depletion
(CADD) (57), Polyphen 2-HDIV (58), and sorting intolerant from
tolerant (SIFT) (59), and analyzed the missense variants based
on whether they were confirmed GT mutants, presumptive GT
mutants, alloantigens, or novel variants. We anticipated that the
confirmed and presumptive GT mutants would be judged to have
the highest likelihood of being deleterious, the alloantigens would
have the lowest likelihood, and the novel variants would have the
greatest range of likelihoods. The results varied with the pre-
diction tool, but in general were consistent with our expectations
(Fig. 4A). Moreover, each of the algorithms identified a cluster of
three presumptive GT variants with a low probability of being
deleterious, and it may be valuable to study these in more detail
[αIIb P76A and β3M321L (64), and H652L (65)]. The concordance
between prediction tools for individual variants is displayed as
a heat map in Fig. S1 and demonstrates variable degrees of
discordance among the tools.
To obtain an estimate of the sensitivity and specificity of each
of the prediction tools in judging missense variants, we assessed
their sensitivity in identifying the confirmed GT and macro/
anisothrombocytopenia mutations as deleterious (positive controls)
and their specificity in identifying the 20 alloantigens as not
being deleterious (negative controls). We then used the results to
create receiver operating characteristic (ROC) curves for each of
the prediction tools (Fig. 4B). All three gave similar patterns,
with areas under the curves of 0.91 [median; 95% confidence
intervals (CI) 0.83, 0.99], 0.90 (CI 0.81, 0.99), and 0.88 (CI 0.80,
0.97) for CADD, Polyphen 2-HDIV, and SIFT, respectively
(Table 1) (P = not significant for all pair-wise comparisons). To
estimate the percentage of the novel variants we identified that
are likely to be deleterious, we applied the cut-off value of each
prediction tool that best differentiated the positive controls from
the negative controls according to the ROC curve and then applied
this value to the novel variants. These optimal cut-off values, ach-
ieved median sensitivities of 98%, 94%, and 69% and specificities
of 75%, 80%, and 95% for CADD, Polyphen 2-HDIV, and SIFT,
respectively. The percentages of novel αIIb missense variants pre-
dicted to be deleterious were 43.0%, 45.6%, and 27.2% for CADD,
Polyphen 2-HDIV, and SIFT, respectively, and the comparable
values for β3 missense variants were 70.6%, 54.4%, and 32.4%,
respectively. Because it is possible that some of the low-frequency
alloantigens are deleterious, we also created ROC curves using only
the 11 of 20 alloantigens that were judged by all three algorithms to
have a low probability of being deleterious (rank scores < 0.5) as
negative controls (Table S1A). As expected, the areas under the
Fig. 3. (A) HEK293 cells (105 cells/mL) were transfected with cDNA harboring the indicated variant in αIIb or β3. Cell lysates were subject to immunoblotting
with antibodies to αIIb and β3. Immunoblot shown is representative of five experiments. (Upper) Color image showing detection with Odyssey system. (Lower)
Black and white image of the examined proteins. (B) Transfected HEK293 cells were analyzed by flow cytometry for αIIbβ3 expression. Cells were incubated
with Alexa488-conjugated mAb 10E5 (10 μg/mL) or (as a control for nonspecific binding) 10 μg/mL Alexa488-conjugated mAb 10E5 in the presence of excess
(125 μg/mL) unlabeled 10E5. The graph depicts the mean ± SEM; n = 5. (C) To assess αIIbβ3 function, DTT (10 mM) was added to the cells and Alexa647-
conjugated fibrinogen binding was assessed via flow cytometry. Binding is expressed as net fibrinogen binding. Data are expressed as mean ± SEM; n = 5.
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curves were higher (1.00, 0.99, and 0.99, respectively). The optimal
cut-off values for each algorithm yielded sensitivities of 98%, 94%,
and 96%, respectively and 100% specificity for all three (Table 1).
The percentages of novel αIIb missense variants predicted to be
deleterious based on these optimal cut-off points were 49.1%,
47.4%, and 59.7%, respectively; the comparable values for β3
were 73.5%, 59.9%, 67.7%, respectively. Thus, only SIFT showed
a major change in the prediction of deleteriousness, and this
reflects the more step-wise nature of the prediction rank scores
with this algorithm in comparison with the more continuous rank
scores with the other algorithms (Fig. 4A).
Concordance in Predictions Among the Three Algorithms. The con-
cordance among the three different algorithms in classifying the
novel variants is shown in Fig. 4C. All three algorithms classi-
fied 22.8% of the ITGA2B and 26.5% of the ITGB3 variants as
deleterious and 43.0% of the ITGA2B and 29.4%% of the ITGB3
variants as nondeleterious. Thus, in total, there was concordance
among all three in classifying 65.8% of the ITGA2B variants and
55.9% of the ITGB3 variants. The greatest discordance was found
in the classification of ITGB3 variants as being deleterious by
both CADD and Polyphen 2-HDIV, but nondeleterious by SIFT,
which accounted for 25.0% of the novel ITGB3 variants.
It is of particular note that Polyphen 2-HDIV and SIFT
identified the αIIb P176H and β3 C547G variants that we found
to have profound defects in surface expression as nearly certain
to be deleterious, with rank scores much higher than the optimal
cut-off values. In contrast, CADD gave both lower rankings (0.66
and 0.61, respectively), but still ones above the optimal cut-off
value of 0.51. As a result, all three algorithms classified these
variants as deleterious. In contrast, the rank scores given to the αIIb
P943A variant were more broadly distributed, with SIFT giv-
ing it the lowest ranking (0.31), Polyphen 2-HDIV an intermediate
ranking (0.50), and CADD the highest ranking (0.80). Based on
each of their optimal cut-off values, this would result in SIFT and
Polyphen2-HDIV classifying this mutation as nondeleterious and
CADD ranking it as deleterious. These results are particularly
interesting because we found that the variant partially decreased
αIIbβ3 expression.
Analysis of the Exome Aggregation Consortium Database. After our
studies were completed, the Exome Aggregation Consortium made
available the results of 60,706 unrelated individuals whose DNA
Fig. 4. (A) A prediction algorithms to assess the likelihood that a variant will be deleterious. The results of the analysis with the algorithms CADD, SIFT, and
Polyphen 2-HDIV are presented for the alloantigens, the presumptive and confirmed GT variants, and the ThromboGenomics and Exome Aggregation Consortium
(ExAC) novel variants. Black arrows on ordinate denote optimal rank score cut-off values. (B) ROC curves of data based on considering confirmed GT and macro/
anisothrombocytopenia as true positives and 20 alloantigens as true negatives. The optimal discriminator points are identified by dots and the corresponding rank
scores are shown next to the dots. (C) Concordance of algorithms in predicting whether novel variants are likely to be deleterious using the optimal cut-offs
determined by the ROC curves. D, deleterious; ND, nondeleterious.
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was sequenced as part of various disease-specific and population
genetic studies. We analyzed the 319 novel variants (that is, those
remaining after removing the GT and macro/anisothrombocytopenia
mutations and the alloantigens) in αIIb (72 of which are also
reported in the ThromboGenomics dataset) and the 216 novel
variants in β3 (49 of which are also reported in the Thrombo-
Genomics dataset) using the optimal cut-off values for each
algorithm based on the ROC curves. CADD, Polyphen 2-HDIV,
and SIFT predicted that 40.8%, 35.7%, and 23.5%, respectively,
of the αIIb and 60.6%, 46.3%, and 29.6%, respectively, of the β3
variants would be deleterious (Fig. 4A), and all three predicted
that 17.6% of αIIb and 22.7% of the β3 variants would be del-
eterious, which are values similar to those predicted using the
ThromboGenomics dataset.
Discussion
Our study highlights the opportunity and challenges in inter-
preting the potential impact of novel variants of αIIbβ3 on re-
ceptor function, with broader implications for interpreting novel
variants in other genes and gaining insights into the evolutionary
pressures that have affected αIIbβ3. We found that three dif-
ferent prediction algorithms were able to differentiate confirmed
GT and macro/anisothrombocytopenia mutations from alloantigens
with reasonably high sensitivity and specificity, but there was some
overlap between the groups and the three algorithms were only
about 60% concordant in classifying novel variants. Thus, it is im-
portant to augment the results of these analyses with additional
data. Table S3 summarizes some of the considerations that a clini-
cian can bring to bear on deciding whether a novel variant in αIIb or
β3 is likely to result in a medically meaningful phenotype. If a pro-
positus is available for study, αIIbβ3 can be quantified by flow
cytometry and its function assessed directly by platelet aggregation
studies using ADP or other agonists that rely on the αIIbβ3 re-
ceptor. Individuals who are heterozygous for mutations that affect
expression of the receptor usually have about 50–60% of the normal
level of platelet αIIbβ3 expression, but there is some overlap be-
tween the values of heterozygotes and normals (66). Homozygotes
have markedly decreased platelet aggregation, but heterozygotes
have little or no decrease in platelet aggregation. If the propositus
is not available, as might occur if a fetus is tested, data from the
prediction tools can be combined with additional data, including
whether the variant affects an amino acid previously associ-
ated with causing GT or macro/anisothrombocytopenia, or
whether the amino acid is highly conserved or is in a region
known to have very stringent structural requirements (for example,
the blades of the β-propeller in αIIb) or to affect ligand binding.
If molecular modeling or molecular dynamics simulations are
available, they can provide more detailed information on the
likely impact of the variant. Additional information can come
from producing a recombinant version of the variant in a cell
line and testing expression and ligand binding, but this requires
considerable time and research expertise, and there are regu-
latory issues in providing information for diagnostic purposes
from assays that are not performed in certified laboratories. The
MAF, if known, can also provide valuable information, because
one would expect a deleterious variant with a high MAF to have
already come to medical attention. By combining all of this in-
formation, the clinician will be able to make a reasoned judgment,
but in many cases there will still be an irreducible level of un-
certainty that needs to be carefully conveyed to the individual
requesting the information.
The results from recent analyses of human exomes and
genomes in large populations provides context for interpreting our
data. The explosive growth in the human population over the past
2,500 y, estimated to be from ∼50 million to ∼7 billion people,
implies departure from population genetic equilibrium and predicts
a large numbers of relatively new variants that have had little time
to undergo selective evolutionary pressure (2, 3, 67, 68). Because
they entered the gene pool recently, these variants are expected
to have a low allele frequency, and vice versa, unless the variant
confers a strong negative effect on fertility in the heterozygous state,
one can surmise that variants with a low MAF entered the gene
pool recently and thus are relatively new. Variants with an MAF <
0.01% probably originated within the past 250 y and those with an
MAF of ∼0.5% probably originated ∼2,500 y ago (68). By defini-
tion, one must sequence large numbers of individuals with high
precision to robustly establish a low MAF, and so such data have
only become available in the past few years (3). Racial differences
also need to be considered, because the African population is the
oldest and thus most diverse, and the European population,
which is presumed to have undergone two population bottle-
necks, probably has had the most rapid recent population growth
(2, 3). Establishing that rare variants are not the result of se-
quencing errors using current methodology requires careful at-
tention, and new methods to minimize the risk of mistaking
sequencing errors for variants are being developed (69).
It is important to recognize the limitations of our study. In
particular, the number of variants identified may be underestimated
if the sequencing does not include all of the exons, as was the
case for several exons in the β3 subunit gene in the ESP study,
representing ∼40% of the exonic bases (Fig. S2), or if the filters are
stringent in the face of relatively low coverage. On the other
Table 1. ROC analysis of αIIbβ3 variants
Algorithm AUC AUC Confidence Interval Sensitivity Specificity Cut-off
Percentage of
novel variants
predicted to be
deleterious
ITGA2B ITGB3
Specificity based on all 20 alloantigens
CADD 0.91 0.83–0.99 0.98 0.75 0.51 43.0 70.6
SIFT 0.88 0.80–0.88 0.69 0.95 0.80 27.2 32.4
Polyphen-2 0.90 0.81–0.90 0.94 0.80 0.58 45.6 54.4
Specificity based on 11 alloantigens with low
probability of being deleterious
CADD 1.00 0.99–1.00 0.98 1 0.46 49.1 73.5
SIFT 0.99 0.98–0.99 0.96 1 0.44 59.7 67.7
Polyphen-2 0.99 0.98–0.99 0.94 1 0.55 47.4 55.9
AUC, area under the ROC curve.
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hand, if there is low sequencing coverage of a region, as was the
case for one complete exon and a portion of another exon in the
αIIb subunit gene in the ESP study, and in the low-coverage U.
K.10KWGS study (70), it is possible that a sequencing error may
be misreported as a variant. To minimize this risk, a series of
filters are applied to the raw sequencing data before making
a final determination of whether a variant is present. In the case of
the U.K.10KWGS study, we found it reassuring that the percentage
of individuals with missense mutations (1.27%) was similar to the
combined value of 1.39% for the other three studies. Moreover, 37
of the 48 missense variants identified in the U.K.10KWGS were
also identified by at least one other study. Overestimation of variant
frequency may also occur if one uses cultured immortalized lym-
phoblastoid cells as the source of DNA because they acquire var-
iants during culture that are not present in the germ line genome
(71). Lymphoblastoid cells were used as a source of DNA only in
the 1000G database. Thus, with the above caveats, we believe our
dataset provides a reasonable reflection of the missense variants in
the populations studied. We did not include variants involving DNA
base pair deletions or insertions because these usually are much less
common than missense variants, and next-generation sequencing is
less accurate in detecting them.
Because not one of the reported GT missense mutants reported
in the literature (HGMD) (Table S1B) was identified in the alleles
included in this analysis, they all presumably have very low MAFs,
implying that they entered the population recently. Independent
support for the recent origin of GT missense mutations comes
from studies of two populations with relatively high rates of GT
because of intragroup marriage, namely Israeli and Palestinian
Arabs and French Manouche gypsies, in which the founder muta-
tions were estimated to be only ∼300–600 and ∼300–400 y old,
respectively (23, 24).
Against this background, our data provide new insights into
the frequency and potential impact of novel variants of αIIbβ3.
In the ∼16,500 individuals studied, we found 114 novel missense
variants affecting ∼10% of the amino acids in αIIb and 68 novel
missense variants affecting ∼9% of the amino acids in β3. Thus,
with the limitations noted above, we found that ∼1.3% of the
population studied harbors a variant in either αIIb or β3.
αIIbβ3 is expressed at ∼100,000 copies per platelet, which is
approximately twice the density required for normal platelet
aggregation (72, 73). As a result, individuals who are heterozy-
gous for GT variants are usually asymptomatic or have relatively
mild symptoms (66, 74–76), and thus are unlikely to be subjected
to selective pressure. Because hemorrhage can result in death
before reaching sexual maturity or during or after child-birth, it
is possible that there would be selective pressure against αIIb
or β3 variants that decreased receptor expression or function in
mammals if they had a lower density of αIIbβ3 receptors than
modern humans or had a high percentage of intragroup matings.
The lack of GT mutations with high MAFs is consistent with
selective pressure against deleterious variants in the distant
past. Platelets are known to be present in all mammals, in-
cluding monotremes (which lay eggs) and marsupials (which do
not have placental births), and so the hemorrhagic risk associated
with placental births cannot explain the appearance of platelets in
mammals (77). To our knowledge however, the densities of αIIbβ3
receptors in monotreme and marsupial platelets have not been
reported, and so it remains possible that placental birth selected
for high receptor density. For comparison, the density of αIIbβ3
receptors on chicken thrombocytes has been reported to be only
∼5% of that of human platelets (78). Because humans increasingly
mate with individuals outside their kinship, heterozygous delete-
rious variants are likely to continue to accumulate. Such variants
may become more consequential in the future as they spread
through the population. Additional variants are likely to enter
the population as de novo variants. Individuals are estimated to
have an average of ∼74 de novo single-nucleotide variants (79);
with a world population of ∼7 billion people, one can expect
more than 500 billion variants per generation in the “humanome,”
enough on average, to affect each of the 3 billion genome bases
more than 100-times over. Thus, with time these variants will in-
crease the likelihood of GT because of double heterozygosity.
Our studies of αIIbβ3 serve as a paradigm for the opportuni-
ties and challenges one can anticipate as we enter the era in
which many individuals (and fetuses) undergo whole-exome and
whole-genome sequencing and want to know whether a novel
variant is deleterious. We applied three algorithms that are
currently used to estimate the percentage of novel variants that
are deleterious and found that using their optimal ROC rank
cut-off values, they predicted between 27.2% and 45.6% of the
novel αIIb variants and between 32.4% and 70.6% of the novel
β3 variants are deleterious; all three predicted that 22.8% of αIIb
variants and 26.5% of β3 variants would be deleterious. These
percentages can be compared with the data from the ESP study
(2), where 74% of nonsynonymous variants (98% of which were
missense variants) were judged deleterious by at least one of
seven algorithms, but only 27.9% met the criterion of being
predicted deleterious by at least four of the seven algorithms. We
would emphasize, however, that the optimal ROC cut-off value
is based on discriminating between two groups, with sensitivity
and specificity given equal weight. Clinically, however, one may
wish to set a minimum sensitivity or specificity to address
a specific goal, for example, choosing a high-sensitivity value so
as to avoid a false-negative diagnosis. This can be achieved by
identifying the rank cut-off value corresponding to the desired
sensitivity/specificity point on the ROC curve.
Two of the novel variants we identified (αIIb P176H and β3
C547G) were predicted by all three algorithms to be deleterious and
we found that both profoundly affected αIIbβ3 expression. We an-
ticipated that the αIIb P176H variant would decrease expression
because of its strategic location and the major change in the side-
chain structure, and that the β3 C547G variant would decrease re-
ceptor expression because of its impact on disulfide bonding. The
αIIb P943A variant was predicted by two of the three algorithms to
be deleterious and we found that it partially decreased αIIbβ3 ex-
pression and did not impair fibrinogen binding induced by DTT. We
suspected that this latter variant would not cause a severe defect in
αIIbβ3 expression or function because, with its relatively high MAF
(0.46%), one would have expected it to have already come to
medical attention in homozygous or double-heterozygous GT
patients. It is possible that hypomorphic variants like P943A, which
partially reduce αIIbβ3 expression, account for some of the wide
range of αIIbβ3 expression observed among apparently healthy
individuals (66). Thus, variants like P943A highlight that even with
the availability of multiple prediction algorithms and an advanced
understanding of a protein’s structure and function, it may be chal-
lenging to predict the functional consequences of any given variant.
Similar considerations bear on the ability to predict whether
a given variant will result in the generation of an alloantigen.
Despite advances in molecular modeling of platelet alloantigens
(47) and predicting the immunogenicity of HLA variants (80)
(www.hlamatchmaker.net/), and the ability of peptides to bind to
specific major histocompatibility molecules (81), it is challenging
to predict the likelihood that a mismatch between parents in
their sequences of αIIb or β3 will result in medically meaningful
fetal and neonatal alloimmune thrombocytopenia because many
other immunologic factors may influence the outcome (82).
Whether β3 variants induce antibodies that affect αVβ3 function,
potentially leading to intrauterine growth restriction or vascular
abnormalities contributing to hemorrhage, or whether de novo
αIIb or β3 variants can result in constitutively active receptors
that may lead to thrombus formation in the placenta (82), are
additional questions of import. It is possible that the latter ab-
normalities have not come to medical attention to date because
they result in fetal loss.
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In conclusion, next-generation sequencing, coupled with ad-
vanced bioinformatics algorithms, is making it possible to both
identify novel missense variants and in many cases make a rea-
soned estimate of the likelihood that the variant will affect
protein expression and/or function. Current algorithms are not
definitive, however, in a substantial percentage of cases, and so
these tools need to be used judiciously and coupled with addi-
tional clinical, laboratory, and population-based data.
Methods
Variant Analysis. This study is part of the ThromboGenomicsworking group (see
SI Methods for description). Data for the present study on αIIb and β3 variants
were obtained from the whole-exome and whole-genome sequencing data
from five different databases: (i) HGMD (www.hgmd.cf.ac.uk/ac/index.php),
which collates published gene lesions responsible for human inherited disease;
(ii) The 1000 Genomes project (1,000GP; www.1000genomes.org), represent-
ing 1,092 individuals of East Asian, South Asian, African, European, and
American ancestry who underwent whole exome or low pass whole genome
sequencing (83); (iii) The U.K.10KWES (www.uk10k.org/), representing up to
4,732 members of the British population (77); (iv) The U.K.10KWGS, repre-
senting 3,781 members of the British population; and (v) The National
Heart, Lung and Blood Institute ESP, representing up to 6,503 Americans of
European and African ancestry (84). We restricted our analyses to single-
nucleotide variants that lead to amino acid substitutions (missense var-
iants). The variants were expressed in a variant call format, starting with
the first based in the human genome reference sequence, which includes
the signal peptide. As a result, the numbers are 31 amino acids higher than
those for mature αIIb and 26 higher than those for mature β3. The effects
of variants were predicted on the standard ITGA2B reference transcript
ENST00000262407 (NM_000419.3, LRG_479t1) and the ITGB3 transcript
ENST0000055948 (NM_000212.2, LRG_481t1) using the variant effect predictor.
Data on coverage of the exons in ITGA2B and ITGB3 are available from the
ESP study and the results shown in Fig. S2. All of the exons in ITG2A had
more than 15× coverage, except for the 5′ end of exon 2 and exon 27. Exons
1–10 in ITGB3 had greater than 15× coverage, but exons 11–15 were not
analyzed. In the U.K.10KWGS study, sequencing was performed to a median
depth of 7.6 reads per sample at single-nucleotide variant sites (70). Each
study defined a series of criteria by which they validated the variants they
identified (83, 84) (www.uk10k.org/data.html#datasets).
Catalogue of GT Missense Mutants. We combined data from the online reg-
istry of GT variants and the five databases identified above into Table S1,
where part A of the table includes data from HGMD only and part B of the
table includes combined data from 1000G, U.K.10KWES, U.K.10KWGS, and
ESP. All reported variants where reviewed and those in which the proposed
GT mutant was shown to lead to a defect in receptor expression and func-
tion in a recombinant system were categorized as confirmed GT mutations.
All other variants where considered presumptive GT mutations. Defects in
GT patients were also characterized as either homozygous or heterozygous
if the information was available. The MAF of each missense variant is
reported based on the combined data from the different databases. Finally,
the database in which the variant was reported is identified.
Analysis of Missense Variants. A complete αIIbβ3 3D model was built using
a combination of X-ray crystallographic data of the αIIbβ3 ectodomain [PDB
ID code 3FCS (18)] and NMR data of the transmembrane and cytoplasmic
domains [PDB ID codes 2K9J (85), 2KNC (86), and 2KV9 (87)]. Missing seg-
ments of the αIIb calf-2 domain (amino acid residues 763–775 and 839–874),
the β3 hybrid domain (amino acids residues 74–79), and the link between the
EGF-1 and EGF-2 domains (amino acids residues 476–483) were built ab initio
using Rosetta 2.2 (88) (Movie S1).
Missense variants were analyzed in terms of: (i) the level of conservation
of the residue position in the alignment of the wild-type sequence of αIIb or
β3 with sequences from different species (the ordinate of the graph in
Fig. 2), and (ii) the severity of the specific amino acid change (the size of
each circle in Fig. 2).
Both the level of conservation across different species and the severity of
the missense variant were assessed based on a mutation score calculated as
the ”sum-of-pairs” score with a modified PET91 substitution matrix (89)
by Valdar and Thornton (see ref. 54 and equation 37 in ref. 55) using the
Scorecons server at www.ebi.ac.uk/thornton-srv/databases/cgi-bin/valdar/
scorecons_server.pl. Severe mutations are less tolerated during evolution
and are therefore characterized by low scores in the substitution matrix, as
opposed to mutations to amino acids with similar properties. Large circle sizes
in Fig. 1 (variant score = 1 − “sum-of-pairs” score) were chosen to represent
severe variants.
In the calculation of sequence conservation, the mutation score consists of
the average of the pair scores calculated for each amino acid in an aligned
column, weighted using the dissimilarity between the sequences comprising
each pair to normalize against sequence redundancy in the alignment. Se-
quence alignments of all human and vertebrate αIIb or β3 sequences were
obtained using the multiple sequence alignment Hidden Markov Model/
clustal W method (56).
Mutagenesis, Cell Transfection, and αIIbβ3 Analysis. For mutagenesis, cell
transfection, and αIIbβ3 analysis, see SI Methods.
Prediction of Variant Impact. We curated the variants using the dbNSFP v2.4
database (database for nonsynonymous SNP’s functional predictions; https://
sites.google.com/site/jpopgen/dbNSFP). This database integrates prediction
scores from several different algorithms, including CADD (57), Polyphen 2-
HDIV (58), and SIFT (59). We then plotted the ranked prediction of CADD,
Polyphen-HDIV, and SIFT for the variants in ITG2A and ITGB3. Variants were
grouped as alloantigens, confirmed GT mutations, presumptive GT muta-
tions, and novel variants. The ROC analysis was done through R package of
pROC v1.7.3 (cran.r-project.org/web/packages/pROC/index.html) (90).
To examine the concordance between the different algorithms, the
ranked scores from the different methods were first displayed as a heat map.
We also displayed the ranked scores for all of the variants by group for
each algorithm.
Statistical Analysis. Each experiment was repeated at least four times. Results
are expressed as mean ± SEM with number of observations n. Data were
analyzed using GraphPad Prism 5 software. Significant differences were
determined using Student t test and considered significant at P ≤ 0.05.
The CI of ROC analysis is calculated by CI function of pROC package (with
default parameters (95% CI through 2,000 stratified bootstrap replicates) (90).
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